Novel Treatment for Stroke at Delayed Timepoints

Competitive Advantages

  • Enhances behavioral recovery after 30 days
  • Reduces neural damage
  • Extends therapeutic window several-fold

Summary

The systemic administration of N,N'-di-1 naphthylguanidine HCl (NAGH) and N,N'-di-p-nitrophenylguanidine HCl (NAD) when administered 24 hours after experimental stroke was found to reduce neural damage and more importantly enhance behavioral recovery thirty days later. This agent has the potential to extend the therapeutic window several-fold over the currently available treatment methods to many stroke patients. Additionally, this agent provides neural protection leading to recovery of functions, such as motor skills. This technology is for the treatment of stroke and has the ability to enhance behavioral recovery following a stroke unlike any other method or drug that is currently approved for stroke treatment.  

 

Novel and Effective Treatment for Stroke 

Desired Partnership

  • License
Patent Information: